ACELUNG - Phase III trial evaluating the role of adjuvant celecoxib in completely resected, high-risk (pN1-2) non-small-cell lung cancer (NSCLC) patients.

Study start date

2004

Study status

closed

Locations

Poland, Medical University of Gdansk

Sponsors and Collaborators:

Eligibility criteria:

Publication: